Department of Liver and Vascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Liver Int. 2011 Jul;31(6):802-9. doi: 10.1111/j.1478-3231.2011.02508.x. Epub 2011 Mar 21.
Studies investigating the association between X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphism Arg399Gln and hepatocellular carcinoma (HCC) risk report conflicting results. The aim of this study was to quantitatively summarize the evidence for such a relationship.
Two investigators independently searched the Medline, Embase, CNKI and Chinese Biomedicine Database. Summary odds ratios (ORs) and 95% confidence intervals (95% CIs) for XRCC1 polymorphism and HCC were calculated in a fixed-effects model (the Mantel-Haenszel method) and a random-effects model (the DerSimonian and Laird method) when appropriate. The pooled ORs were performed for a codominant model (Gln/Gln vs. Arg/Arg, Arg/Gln vs. Arg/Arg), a dominant model (Gln/Gln+Arg/Gln vs. Arg/Arg) and a recessive model (Gln/Gln vs. Arg/Gln+Arg/Arg).
This meta-analysis included 11 case-control studies, which included 2208 HCC cases and 3265 controls. Overall, the variant genotypes (Gln/Gln and Arg/Gln) of Arg399Gln were not associated with HCC risk when compared with the wild-type Arg/Arg homozygote (Gln/Gln vs. Arg/Arg, OR=1.01, 95% CI=0.79-1.28; Arg/Gln vs. Arg/Arg, OR=1.09, 95% CI=0.81-1.45). Similarly, no associations were found in the dominant and recessive models (dominant model, OR=1.12, 95% CI=0.85-1.47; recessive model, OR=0.99, 95% CI=0.79-1.25). Limiting the analysis to the studies within Hardy-Weinberg equilibrium, the results were persistent and robust. When stratifying for ethnicity, country/region and source of controls, no evidence of a significant association was observed in any subgroup. No publication bias was found in the present study.
No association is found between the XRCC1 polymorphism Arg399Gln and the risk of HCC.
研究 X 射线修复交叉互补基因 1（XRCC1）遗传多态性 Arg399Gln 与肝细胞癌（HCC）风险之间的关联的研究报告结果相互矛盾。本研究的目的是定量总结这种关系的证据。
两位研究者独立检索了 Medline、Embase、CNKI 和中国生物医学数据库。在适当的情况下，使用固定效应模型（Mantel-Haenszel 方法）和随机效应模型（DerSimonian 和 Laird 方法）计算 XRCC1 多态性与 HCC 的汇总比值比（OR）和 95%置信区间（95%CI）。对于共显性模型（Gln/Gln 与 Arg/Arg、Arg/Gln 与 Arg/Arg）、显性模型（Gln/Gln+Arg/Gln 与 Arg/Arg）和隐性模型（Gln/Gln 与 Arg/Gln+Arg/Arg）进行了汇总 OR 分析。
本荟萃分析纳入了 11 项病例对照研究，共包括 2208 例 HCC 病例和 3265 例对照。总体而言，与野生型 Arg/Arg 纯合子相比，Arg399Gln 的变体基因型（Gln/Gln 和 Arg/Gln）与 HCC 风险无关（Gln/Gln 与 Arg/Arg，OR=1.01，95%CI=0.79-1.28；Arg/Gln 与 Arg/Arg，OR=1.09，95%CI=0.81-1.45）。同样，在显性和隐性模型中也没有发现关联（显性模型，OR=1.12，95%CI=0.85-1.47；隐性模型，OR=0.99，95%CI=0.79-1.25）。当将分析限制在符合 Hardy-Weinberg 平衡的研究中时，结果是持续和稳健的。按种族、国家/地区和对照来源进行分层时，在任何亚组中均未发现显著关联的证据。本研究未发现发表偏倚。
XRCC1 多态性 Arg399Gln 与 HCC 风险之间没有关联。
